CRISPR

News

CRISPR gene editing stocks fall after Editas CEO resigns

Shares in firms developing therapies based on CRISPR gene editing technology have fallen after the resignation of the CEO of one of the leading biotechs in the field, Editas.

Views & Analysis

2018 Review pharma Alzheimer's CRISPR AI

2018 in review: Alzheimer’s falters while oncology shines

Going into 2018 you might have expected this to be the year of Alzheimer’s drugs, with several promising trials underway – but unfortunately the last 12 months have been marked by failure a

News

AZ and CRUK team up to go all-in on CRISPR

AstraZeneca and Cancer Research UK are collaborating to launch a centre of excellence in genetic screening, cancer modelling and big data processing that will develop CRISPR technology to b

Partner Content